Logo

Precision BioSciences Raises $25.6M in Series A Financing

May 11, 2015 | staff reporter

NEW YORK (GenomeWeb) – Precision BioSciences today announced it has closed a $25.6 million Series A financing round.

Life sciences investor VenBio led the round, joined by Fidelity Biosciences, Amgen Ventures, Baxter Ventures, Osage University Partners, the Longevity Fund, and two unnamed public market investors.

"This financing will allow us to expand beyond our successful efforts to develop the leading next-gen genome editing platform and significantly accelerate the development of our genome-edited product pipeline," Precision BioSciences CEO Matthew Kane said in a statement.

Precision BioSciences' Arcus genome editing platform can remove, insert, and modify DNA at any location in the genome, the firm said in a statement, combining the target site flexibility of CRISPR/Cas9 along with the site specificity of homing endonucleases.

The Research Triangle Park, North Carolina-based company has signed collaborations to use its genome engineering platform in castor plants and corn.

Filed under

Applied Markets: Ag-Bio, Veterinary, Forensics, Food Safety, & Environmental Testing
Business News
Gene Editing, Gene Silencing, & CRISPR
Precision Biosciences
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.